Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is 1 of the best biotech penny stocks to bargain according to analysts. On December 17, Barclays expert Etzer Darout raised the firm’s terms people connected Iovance Biotherapeutics to $10 from $9, portion keeping an Overweight standing connected the shares. This announcement was made arsenic portion of the firm’s 2026 projections, wherever it revised its valuation targets for the biotech industry.

Earlier successful Q3 2025, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) highlighted a full merchandise gross of $68 million, which was a 13% sequential increase. The superior operator was Amtagvi sales, which reached $58 million, portion Proleukin contributed ~$10 million. The institution besides reaffirmed its full-year 2025 gross guidance of $250 to $300 million. Management remains optimistic astir Amtagvi’s growth, projecting highest US income successful precocious melanoma to transcend $1 billion. This maturation is supported by an expanding web of 80+ Authorized Treatment Centers crossed ~40 states.

A large operational displacement is planned for aboriginal 2026, erstwhile Iovance volition centralize each Amtagvi and objective manufacturing astatine its interior facility, the Iovance Cell Therapy Center/iCTC. This determination is designed to destruct reliance connected declaration manufacturers, maximize capacity, and further thrust gross margins toward a semipermanent extremity of implicit 70%.

Beyond melanoma, Iovance is aggressively pursuing a importantly larger marketplace successful non-small compartment lung cancer/NSCLC. Interim information from the IOV-LUN-202 proceedings showed a best-in-class illustration with an nonsubjective effect complaint of 26% and a median duration of effect that was not reached astatine 25 months. Enrollment of ~80 patients is expected to decorativeness successful 2026, supporting a imaginable supplemental BLA and a commercialized motorboat successful H2 2027.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is simply a commercial-stage biopharmaceutical institution that develops and commercializes compartment therapies utilizing autologous tumor-infiltrating lymphocytes for the attraction of metastatic melanoma and different coagulated tumor cancers successful the US.

While we admit the imaginable of IOVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.